	US 11,912,745 B2
	ICAM-1 targeted fusion enzymes
Silvia Muro, Gaithersburg, MD (US); Jing Chen, Nanjing (CN); Melani Solomon, Laurel, MD (US); and Kevin Gray, Washington, DC (US)
Assigned to University of Maryland, College Park, College Park, NY (US)
Filed by University of Maryland, College Park, College Park, MD (US)
Filed on Jan. 7, 2022, as Appl. No. 17/571,415.
Application 17/571,415 is a continuation of application No. 16/951,774, filed on Nov. 18, 2020, granted, now 11,248,029.
Claims priority of provisional application 62/936,988, filed on Nov. 18, 2019.
Prior Publication US 2022/0204573 A1, Jun. 30, 2022
Int. Cl. C07K 14/47 (2006.01); C12N 9/16 (2006.01); C12N 9/24 (2006.01); C12N 9/40 (2006.01); C07K 14/705 (2006.01)

CPC C07K 14/47 (2013.01) [C12N 9/16 (2013.01); C12N 9/2402 (2013.01); C12N 9/2465 (2013.01); C12Y 302/01022 (2013.01); C12Y 302/01045 (2013.01); C07K 2319/055 (2013.01); C07K 2319/21 (2013.01); C07K 2319/33 (2013.01); C07K 2319/50 (2013.01)]

12 Claims

1. A fusion protein comprising:

i) five to ten tandemly connected intercellular adhesion molecule-1 (ICAM-1) targeting segments, wherein each ICAM-1 targeting segment comprises SEQ ID NO: 27 (NNQKLVNIKEKVAQIEA);

ii) an enzyme segment that can be catalytically active at the pH of a lysosome, wherein the enzyme segment comprises Acid sphingomyelinase (ASM), Alpha galactosidase, or Glucocerebrosidase;

iii) a first protease cleavage sequence segment between i) and ii), and optionally, one or more of:

iv) a secretion signal;

v) a protein purification tag; and

vi) a second protease cleavage sequence.